OPL.AX Opyl Limited (ASX) A$0.02 on 23 Mar 2026: Oversold bounce may lift price

OPL.AX stock closed at A$0.02 on 23 Mar 2026, marking an oversold bounce setup after a -12.00% five-day pullback. Market Closed for the ASX session. Low liquidity and a 50-day average A$0.02 price increase suggest short-term mean reversion. Traders should note the thin volume of 76,364.00 shares versus an average of 1,073,832.00 shares. We outline technical triggers, fundamentals, and a model forecast to identify a disciplined entry for a tactical oversold bounce.

OPL.AX stock: Price, volume and session snapshot

Opyl Limited (OPL.AX) ended the ASX session at A$0.02 on 23 Mar 2026. The day range was A$0.02–A$0.02 and volume hit 76,364.00 shares. The 50-day average price sits at A$0.02 and the 200-day average is A$0.02, which shows prices trading near longer-term averages. Market cap is A$5,406,896.00, and shares outstanding are 245,768,000.00.

Fundamentals and valuation for OPL.AX stock

Opyl operates in Healthcare information services and reports EPS -A$0.01 and PE -2.20 (negative). Price to sales is 13.60, and cash per share is A$0.00 when rounded to two decimals. Revenue per share is A$0.00 on the latest TTM. The company has modest working capital pressure with a current ratio of 0.77 and free cash flow per share of -A$0.01.

Technical oversold bounce setup for OPL.AX stock

Price weakness over the past five days at -12.00% and a year low of A$0.01 create an oversold condition. Average daily liquidity is low at 1,073,832.00 shares, so small orders move price. RSI and many indicators read as unreliable due to volume, but a daily close above A$0.03 would validate a short-term bounce. Traders should use tight risk controls because volatility can spike on low volume.

Meyka AI rates OPL.AX with a score out of 100 and model outlook

Meyka AI rates OPL.AX with a score out of 100: 71.09 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a tactical bounce to A$0.03, which implies a 36.36% upside versus the current A$0.02. Forecasts are model-based projections and not guarantees.

Catalysts, risks and sector context for OPL.AX stock

Catalysts include improved clinical trial wins and higher social media marketing contracts. The Healthcare sector YTD is -12.20%, which pressures peers. Key risks include continued cash flow weakness, negative margins, and low liquidity that magnify downside. Analyst consensus and company updates will drive next moves. Check Opyl announcements and filings before trading via the company site and ASX.

Trading strategy: practical oversold bounce rules for OPL.AX stock

Enter only on clear confirmation, such as a volume spike and a close above A$0.03. Use position sizes under 1.00% of portfolio value for speculative trades. Place stop-losses below the recent low at A$0.01. Consider scaling out at A$0.03 and A$0.04 to capture a measured bounce while limiting exposure to headline risk.

Final Thoughts

Key takeaway: OPL.AX stock closed A$0.02 on 23 Mar 2026 and shows a classic oversold bounce setup after a -12.00% five-day slide. Fundamentals remain challenged with negative EPS and thin cash buffers. Liquidity is low, so trades should be small and rule-based. Meyka AI’s model projects a tactical bounce to A$0.03, an implied 36.36% upside from A$0.02. For a fuller recovery, we see a stretch target of A$0.05 if revenue growth and cash flow improve. Forecasts are model-based projections and not guarantees. Use stops at A$0.01 and confirm entries with volume and company news. For disclosures and the latest filings see Opyl’s website and ASX announcements. Meyka AI provided the AI-powered market analysis in this report.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.